Talazoparib, a Poly (ADP-ribose) polymerase (PARP) inhibitor, showed maximum efficacy in breast cancer cells due to its strong binding to DNA by trapping PARP–DNA complexes [179]. This evidence concerns the gene PARP1 and breast carcinoma.